Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The second phase of buybacks occurred from October 27 to November 5, following an initial phase from September 15 to September 24 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is dominated by foreign brands, but there is significant room for growth in China, where the penetration rate is currently low compared to mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is experiencing a shift, with hyaluronic acid and botulinum toxin being the leading materials, comprising 98% of the injection market [10]. - The domestic market for collagen is growing rapidly, with a projected compound annual growth rate of 41.45% from 2023 to 2027 [11].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share repurchase operations this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks are segmented into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is seen as a promising area for growth, with significant potential for market penetration in China compared to more mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is currently experiencing a transition, with hyaluronic acid and botulinum toxin being the leading products [10][11]. - The domestic market for botulinum toxin is still developing, with a low penetration rate compared to the U.S., indicating room for growth [13][14].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月6日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 2 頁 共 8 頁 v 1.3.0 | | | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | 說明 | | A 股（上海證券交易所科創板，股份代號：688366） | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年11月6日该公司斥资74.69万港元回购2.71万 股，回购价格为每股27.52-27.58港元。 ...

格隆汇11月6日丨昊海生物科技(06826.HK)发布公告，2025年11月6日耗资74.69万港元回购2.71万股，回 购价格每股27.52-27.58港元。 ...

Core Viewpoint - Haohai Biological Technology (06826) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Buyback Details - The company plans to repurchase 27,100 shares at a total cost of HKD 746,900 [1] - The buyback price ranges from HKD 27.52 to HKD 27.58 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年11月6日 | 1). | 於 2025 年9月15日回購股份但尚未註銷 | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | | | 變動日期 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | 10,000 | % | HKD | 27.68 | | | 變動日期 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | 18,400 | % | HKD | 28 | | | 變動日期 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | 23,500 | % | HKD | 27.63 | | | 變動日期 2025年9月1 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

Core Viewpoint - Haohai Biological Technology (06826.HK) announced a share buyback on November 5, 2025, spending HKD 805,700 to repurchase 29,600 shares at a price range of HKD 27 to HKD 27.36 per share [1] Summary by Category - **Company Actions** - The company executed a share buyback, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 805,700 [1] - The number of shares repurchased was 29,600 [1] - **Financial Details** - The buyback price per share ranged from HKD 27 to HKD 27.36 [1]

Core Viewpoint - Haohai Biological Technology announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Company Actions - The company plans to repurchase 29,600 shares at a total cost of HKD 805,700 [1] - The buyback price per share ranges from HKD 27 to HKD 27.36 [1]